Wenping Lu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Wenping Lu has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
Zhili Zhuo
Department of Oncology, Guang’anmen Hospital, China Academy of Chinese Medical Sciences, China
19 shared publicationsYongjia Cui
16 shared publicationsDongni Zhang
14 shared publicationsHeting Mei
Department of Oncology, China Academy of Chinese Medical Sciences Guang’anmen Hospital
14 shared publicationsLei Chang
Guang’anmen Hospital, China Academy of Chinese Medical Sciences
12 shared publicationsXiaoqing Wu
Oncology Department, China Academy of Chinese Medical Sciences Guang’anmen Hospital, Beijing, China
9 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1911296
Immune evasion driven by lipid metabolic reprogramming in endocrine-resistant HR+ breast cancer: antigen presentation defects and T-cell dysfunction
Endocrine therapy has improved the prognosis of patients with hormone receptor-positive (HR + ) breast cancer. However, acquired resistance remains a major cause of recurrence and progression, and the limited response of this subtype to immunotherapy highlights the need to better understand the mechanisms underlying immune escape. Recent studies indicate that, in addition to an immunosuppressive microenvironment, alterations in antigen processing and presentation may also contribute to immune escape, although systematic integration of these mechanisms remains lacking. Lipid metabolic reprogramming, as a key feature of tumor metabolic remodeling, supports tumor cell survival and adaptive evolution in endocrine-resistant HR + breast cancer and may also regulate antitumor immune responses through multilevel mechanisms. At the tumor cell level, enhanced fatty acid oxidation, increased lipid synthesis, and altered cholesterol metabolism may affect tumor immune visibility by influencing antigen presentation-related processes, including MHC class I-associated pathways. Within the immune microenvironment, lipid accumulation may contribute to dendritic cell dysfunction and promote the polarization of tumor-associated macrophages toward immunosuppressive phenotypes, thereby impairing antigen presentation. Consequently, persistent and inefficient antigen stimulation may promote T-cell dysfunction and exhaustion. This article systematically integrates the role of lipid metabolism in antigen presentation and T-cell regulation, and proposes a dysfunctional multilevel mechanistic axis of “lipid metabolism-antigen presentation-T-cell function“, providing a theoretical basis for understanding immune evasion associated with endocrine resistance and for developing combination therapeutic strategies.
- 3 September 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1911296
Open AccessImmune evasion driven by lipid metabolic reprogramming in endocrine-resistant HR+ breast cancer: antigen presentation defects and T-cell dysfunction
Endocrine therapy has improved the prognosis of patients with hormone receptor-positive (HR + ) breast cancer. However, acquired resistance remains a major cause of recurrence and progression, and the limited response of this subtype to immunotherapy highlights the need to better understand the mechanisms underlying immune escape. Recent studies indicate that, in addition to an immunosuppressive microenvironment, alterations in antigen processing and presentation may also contribute to immune escape, although systematic integration of these mechanisms remains lacking. Lipid metabolic reprogramming, as a key feature of tumor metabolic remodeling, supports tumor cell survival and adaptive evolution in endocrine-resistant HR + breast cancer and may also regulate antitumor immune responses through multilevel mechanisms. At the tumor cell level, enhanced fatty acid oxidation, increased lipid synthesis, and altered cholesterol metabolism may affect tumor immune visibility by influencing antigen presentation-related processes, including MHC class I-associated pathways. Within the immune microenvironment, lipid accumulation may contribute to dendritic cell dysfunction and promote the polarization of tumor-associated macrophages toward immunosuppressive phenotypes, thereby impairing antigen presentation. Consequently, persistent and inefficient antigen stimulation may promote T-cell dysfunction and exhaustion. This article systematically integrates the role of lipid metabolism in antigen presentation and T-cell regulation, and proposes a dysfunctional multilevel mechanistic axis of “lipid metabolism-antigen presentation-T-cell function“, providing a theoretical basis for understanding immune evasion associated with endocrine resistance and for developing combination therapeutic strategies.
- Open Access
- 19 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1889059
Asymptomatic extreme troponin elevation preceding fatal clinically suspected sintilimab-associated myocarditis: a case report
Background: Immune checkpoint inhibitors (ICIs) have been increasingly integrated into first-line systemic treatment strategies for advanced or metastatic gastroesophageal cancers. ICI-associated myocarditis is an uncommon but potentially fatal immune-related adverse event. Early recognition is particularly challenging when severe myocardial injury precedes typical cardiac symptoms. Case summary: A 71-year-old man with advanced gastric adenocarcinoma with liver, abdominal cavity, and retroperitoneal metastases received first-line oxaliplatin, S-1, and sintilimab on December 30, 2025. Baseline cardiac biomarkers before treatment were within normal limits, and baseline echocardiography showed preserved left ventricular systolic function without regional wall motion abnormality. He was rehospitalized for his second course of chemotherapy on January 23, 2026, without chest pain, palpitations, or dyspnea. Routine laboratory testing unexpectedly revealed extreme myocardial injury, with NT-proBNP 1263 pg/ml, cardiac troponin I (cTnI) >25, 000 ng/L, creatine kinase (CK) 5, 205 U/L, myoglobin (MYO) >1, 000 μg/L, and CK-MB mass 112.39 μg/L. Electrocardiography remained broadly similar to the baseline tracing of sinus rhythm with complete right bundle branch block, without a diagnostic acute ST-segment elevation pattern. Coronary angiography did not identify an acute culprit lesion sufficient to explain the biomarker elevation. Serial echocardiography showed new wall motion abnormality and progressive decline in left ventricular ejection fraction. Given the temporal relationship with PD-1 blockade, the absence of an angiographic culprit lesion, evolving myocardial dysfunction, and marked cardiac biomarker elevation, a clinical diagnosis of probable sintilimab-associated myocarditis was made. Intravenous methylprednisolone, intravenous immunoglobulin, and intensive supportive treatment were administered. However, myocardial biomarkers remained markedly abnormal, and overt cardiac symptoms emerged only later in the course, followed by hemodynamic instability and terminal circulatory collapse. The patient died of fulminant myocarditis with cardiogenic shock on February 1, 2026. Conclusion: This case illustrates a biomarker-first presentation of probable ICI-associated myocarditis, in which catastrophic myocardial injury was detected before typical cardiac symptoms became apparent. Absence of chest pain or dyspnea should not reassure clinicians when marked troponin elevation occurs shortly after ICI exposure.
- 19 August 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1889059
Open AccessAsymptomatic extreme troponin elevation preceding fatal clinically suspected sintilimab-associated myocarditis: a case report
Background: Immune checkpoint inhibitors (ICIs) have been increasingly integrated into first-line systemic treatment strategies for advanced or metastatic gastroesophageal cancers. ICI-associated myocarditis is an uncommon but potentially fatal immune-related adverse event. Early recognition is particularly challenging when severe myocardial injury precedes typical cardiac symptoms. Case summary: A 71-year-old man with advanced gastric adenocarcinoma with liver, abdominal cavity, and retroperitoneal metastases received first-line oxaliplatin, S-1, and sintilimab on December 30, 2025. Baseline cardiac biomarkers before treatment were within normal limits, and baseline echocardiography showed preserved left ventricular systolic function without regional wall motion abnormality. He was rehospitalized for his second course of chemotherapy on January 23, 2026, without chest pain, palpitations, or dyspnea. Routine laboratory testing unexpectedly revealed extreme myocardial injury, with NT-proBNP 1263 pg/ml, cardiac troponin I (cTnI) >25, 000 ng/L, creatine kinase (CK) 5, 205 U/L, myoglobin (MYO) >1, 000 μg/L, and CK-MB mass 112.39 μg/L. Electrocardiography remained broadly similar to the baseline tracing of sinus rhythm with complete right bundle branch block, without a diagnostic acute ST-segment elevation pattern. Coronary angiography did not identify an acute culprit lesion sufficient to explain the biomarker elevation. Serial echocardiography showed new wall motion abnormality and progressive decline in left ventricular ejection fraction. Given the temporal relationship with PD-1 blockade, the absence of an angiographic culprit lesion, evolving myocardial dysfunction, and marked cardiac biomarker elevation, a clinical diagnosis of probable sintilimab-associated myocarditis was made. Intravenous methylprednisolone, intravenous immunoglobulin, and intensive supportive treatment were administered. However, myocardial biomarkers remained markedly abnormal, and overt cardiac symptoms emerged only later in the course, followed by hemodynamic instability and terminal circulatory collapse. The patient died of fulminant myocarditis with cardiogenic shock on February 1, 2026. Conclusion: This case illustrates a biomarker-first presentation of probable ICI-associated myocarditis, in which catastrophic myocardial injury was detected before typical cardiac symptoms became apparent. Absence of chest pain or dyspnea should not reassure clinicians when marked troponin elevation occurs shortly after ICI exposure.
- Open Access
- 28 May 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1848363
Environmental endocrine disruptors and endometrial cancer risk: a systematic review and meta-analysis of cadmium and polychlorinated biphenyls, with emerging evidence on PFAS, phthalates, and bisphenols
Background: Environmental endocrine-disrupting chemicals (EDCs) have been implicated in hormone-related carcinogenesis, however, their associations with endometrial cancer risk remain unclear; therefore, this study aimed to systematically evaluate the relationship between multiple classes of EDCs and the endometrial cancer risk. Methods: The PubMed, Web of Science, EMBASE, and Cochrane Library databases were searched for studies published up to November 30, 2025. Studies evaluating the association between EDCs exposure and endometrial cancer risk were included. When sufficient data were available, meta-analyses of cadmium and polychlorinated biphenyls (PCBs) were conducted using random-effects models, with subgroup and sensitivity analyses performed. Evidence on per- and polyfluoroalkyl substances (PFAS), phthalates, and bisphenols was summarized through a structured narrative review. All statistical analyses were performed using Stata 18.0. Results: A total of 14 studies were included. The meta-analysis showed that higher cadmium exposure was associated with an increased risk of endometrial cancer (RR = 1.22, 95% CI: 1.01-1.47), with considerable heterogeneity across studies (I²= 72.17%). Subgroup analyses suggested that the association was not statistically significant for dietary cadmium exposure or among women undergoing hormone therapy, and a marginally positive association was observed in postmenopausal women (RR = 1.27, 95% CI: 0.99-1.64). No significant association was identified between PCBs exposure and endometrial cancer risk (RR = 1.11, 95% CI: 0.79-1.56), and heterogeneity was low (I² = 0.0%). Findings from case-control studies and subgroup analyses stratified by PCBs functional classification (Estrogenic and Enzyme-inducing types) were consistent, with no significant associations detected. Owing to the limited number of available studies, quantitative synthesis was not feasible for PFAS, phthalates, or bisphenols. Conclusion: Current evidence suggests a potential link between cadmium exposure and endometrial cancer, though substantial heterogeneity warrants caution. No consistent association was observed for PCBs. Evidence on emerging EDCs, including PFAS, phthalates, and bisphenols, remains limited and exploratory. Well-designed prospective studies with improved exposure assessment and standardized confounder control are needed.
- 28 May 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1848363
Open AccessEnvironmental endocrine disruptors and endometrial cancer risk: a systematic review and meta-analysis of cadmium and polychlorinated biphenyls, with emerging evidence on PFAS, phthalates, and bisphenols
Background: Environmental endocrine-disrupting chemicals (EDCs) have been implicated in hormone-related carcinogenesis, however, their associations with endometrial cancer risk remain unclear; therefore, this study aimed to systematically evaluate the relationship between multiple classes of EDCs and the endometrial cancer risk. Methods: The PubMed, Web of Science, EMBASE, and Cochrane Library databases were searched for studies published up to November 30, 2025. Studies evaluating the association between EDCs exposure and endometrial cancer risk were included. When sufficient data were available, meta-analyses of cadmium and polychlorinated biphenyls (PCBs) were conducted using random-effects models, with subgroup and sensitivity analyses performed. Evidence on per- and polyfluoroalkyl substances (PFAS), phthalates, and bisphenols was summarized through a structured narrative review. All statistical analyses were performed using Stata 18.0. Results: A total of 14 studies were included. The meta-analysis showed that higher cadmium exposure was associated with an increased risk of endometrial cancer (RR = 1.22, 95% CI: 1.01-1.47), with considerable heterogeneity across studies (I²= 72.17%). Subgroup analyses suggested that the association was not statistically significant for dietary cadmium exposure or among women undergoing hormone therapy, and a marginally positive association was observed in postmenopausal women (RR = 1.27, 95% CI: 0.99-1.64). No significant association was identified between PCBs exposure and endometrial cancer risk (RR = 1.11, 95% CI: 0.79-1.56), and heterogeneity was low (I² = 0.0%). Findings from case-control studies and subgroup analyses stratified by PCBs functional classification (Estrogenic and Enzyme-inducing types) were consistent, with no significant associations detected. Owing to the limited number of available studies, quantitative synthesis was not feasible for PFAS, phthalates, or bisphenols. Conclusion: Current evidence suggests a potential link between cadmium exposure and endometrial cancer, though substantial heterogeneity warrants caution. No consistent association was observed for PCBs. Evidence on emerging EDCs, including PFAS, phthalates, and bisphenols, remains limited and exploratory. Well-designed prospective studies with improved exposure assessment and standardized confounder control are needed.
- Open Access
- 20 May 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Global trends in fertility-preserving treatment for endometrial cancer: a bibliometric analysis, 2005–2024
To quantitatively map and visualize global research trends, key contributors, and thematic evolution in fertility-preserving treatment for endometrial cancer from 2005 to 2024. Research publications on fertility-preserving treatment for endometrial cancer were obtained from the Web of Science Core Collection database. We employed CiteSpace and VOSviewer to analyze authors, journals, countries, institutions, citations, references, and keywords. From 2005 to 2024, a total of 1106 publications were published in related fields. Research on fertility-preserving treatment for endometrial cancer progressed rapidly, exhibiting an upward trend in annual publications. China, Fudan University, and Xiaojun Chen were the most productive country, institution, and author, respectively. The journal that published the most articles and received the highest number of citations was Gynecologic Oncology. Keyword co-occurrence analysis identified three major research clusters. These clusters primarily encompass treatment modalities, key clinical outcomes, and risk factors. Molecular classification was a research hotspot from 2021 to 2024. This bibliometric analysis provides insight into current trends and future directions in fertility-preserving treatments for endometrial cancer. Recent research has prominently emphasized molecular classification, with immunotherapy potentially emerging as a promising treatment modality.
- 20 May 2026
- Published by Springer Nature in Discover Oncology
- Vol. 17 (1)
Open AccessGlobal trends in fertility-preserving treatment for endometrial cancer: a bibliometric analysis, 2005–2024
To quantitatively map and visualize global research trends, key contributors, and thematic evolution in fertility-preserving treatment for endometrial cancer from 2005 to 2024. Research publications on fertility-preserving treatment for endometrial cancer were obtained from the Web of Science Core Collection database. We employed CiteSpace and VOSviewer to analyze authors, journals, countries, institutions, citations, references, and keywords. From 2005 to 2024, a total of 1106 publications were published in related fields. Research on fertility-preserving treatment for endometrial cancer progressed rapidly, exhibiting an upward trend in annual publications. China, Fudan University, and Xiaojun Chen were the most productive country, institution, and author, respectively. The journal that published the most articles and received the highest number of citations was Gynecologic Oncology. Keyword co-occurrence analysis identified three major research clusters. These clusters primarily encompass treatment modalities, key clinical outcomes, and risk factors. Molecular classification was a research hotspot from 2021 to 2024. This bibliometric analysis provides insight into current trends and future directions in fertility-preserving treatments for endometrial cancer. Recent research has prominently emphasized molecular classification, with immunotherapy potentially emerging as a promising treatment modality.
- Open Access
- 5 March 2026
- Published by Springer Nature in Clinical Proteomics
- Vol. 23 (1)
IL3RA identified as novel biomarker and therapeutic target for ER+ breast cancer through plasma proteome-wide mendelian randomization and TCGA database analysis
Estrogen receptor-positive (ER+) breast cancer, a leading cause of female cancer mortality, faces therapeutic challenges due to endocrine resistance. Plasma proteins, bridging genetic variation and disease phenotypes, offer potential biomarkers and therapeutic targets, yet their causal roles in the pathogenesis of ER+ breast cancer remain underexplored. Using two-sample Mendelian randomization (TSMR) and Bayesian colocalization, we analyzed associations between plasma protein quantitative trait loci from deCODE/Fenland cohorts and ER+ breast cancer. DSigDB predicted drugs targeting identified protein, while TCGA assessed the prognostic value. TSMR identified 38 causal plasma proteins (deCODE), with Bayesian analysis prioritizing 12 candidates. IL3RA emerged as stable and novel protective factor, validated in Fenland data. TCGA revealed reduced IL3RA expression in ER+ tumors, with higher levels correlating with improved survival and favorable clinicopathological features, particularly in ER+/PR+ cases. Tumor microenvironment analysis revealed that IL3RA expression levels significantly correlated with immune landscape alterations in ER+ breast cancer. Immune infiltration analysis demonstrated significant associations between IL3RA expression levels and multiple immune cell populations in ER+ breast cancer, particularly CD8+ T cells, neutrophils, M0 macrophages, and M2 macrophages. DSigDB identified panobinostat, arbutin, clindamycin, cimetidine, and chlorzoxazone as IL3RA-targeting drugs. Our study identified IL3RA as novel biomarker and therapeutic target for ER+ breast cancer. Further validation and mechanistic studies are warranted to advance precision oncology strategies for ER+ breast cancer management.
- 5 March 2026
- Published by Springer Nature in Clinical Proteomics
- Vol. 23 (1)
Open AccessIL3RA identified as novel biomarker and therapeutic target for ER+ breast cancer through plasma proteome-wide mendelian randomization and TCGA database analysis
Estrogen receptor-positive (ER+) breast cancer, a leading cause of female cancer mortality, faces therapeutic challenges due to endocrine resistance. Plasma proteins, bridging genetic variation and disease phenotypes, offer potential biomarkers and therapeutic targets, yet their causal roles in the pathogenesis of ER+ breast cancer remain underexplored. Using two-sample Mendelian randomization (TSMR) and Bayesian colocalization, we analyzed associations between plasma protein quantitative trait loci from deCODE/Fenland cohorts and ER+ breast cancer. DSigDB predicted drugs targeting identified protein, while TCGA assessed the prognostic value. TSMR identified 38 causal plasma proteins (deCODE), with Bayesian analysis prioritizing 12 candidates. IL3RA emerged as stable and novel protective factor, validated in Fenland data. TCGA revealed reduced IL3RA expression in ER+ tumors, with higher levels correlating with improved survival and favorable clinicopathological features, particularly in ER+/PR+ cases. Tumor microenvironment analysis revealed that IL3RA expression levels significantly correlated with immune landscape alterations in ER+ breast cancer. Immune infiltration analysis demonstrated significant associations between IL3RA expression levels and multiple immune cell populations in ER+ breast cancer, particularly CD8+ T cells, neutrophils, M0 macrophages, and M2 macrophages. DSigDB identified panobinostat, arbutin, clindamycin, cimetidine, and chlorzoxazone as IL3RA-targeting drugs. Our study identified IL3RA as novel biomarker and therapeutic target for ER+ breast cancer. Further validation and mechanistic studies are warranted to advance precision oncology strategies for ER+ breast cancer management.
- Open Access
- 4 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1745011
Immune checkpoint inhibitor-induced bullous pemphigoid: a systematic review of clinical characteristics and outcomes based on case reports
Objective: Immune checkpoint inhibitor-induced bullous pemphigoid (ICI-BP) is a rare and complex cutaneous immune-related adverse event (cirAE) that often impacts the continuation of ICI therapy. Currently, there are no prospective clinical studies addressing the optimal management of BP alongside ICI continuation, with existing evidence largely derived from case reports or series. This study systematically analyzes published case reports and series to compile evidence regarding the management of ICI-BP and ICI rechallenge, aiming to inform clinical practice. Methods: A comprehensive search of the PubMed, Embase, and Web of Science Core Collection (WoS CC) databases was conducted from their inception to identify eligible case reports and series. Relevant data were extracted using a standardized form. A total of 116 cases from 89 publications were included in the analysis. Results: There was no discernible disparity in the final response rate between patients with mild and severe BP (p > 0.05); however, the percentage of severe patients undergoing escalation therapy was notably higher (p < 0.001). This suggests that employing an active treatment approach based on disease severity effectively ameliorated the potentially graver prognosis in severe cases. Following BP management, 18 patients underwent rechallenge with ICI therapy, with an overall low BP recurrence rate (22.2%), indicating that most patients tolerated the resumption well. Nevertheless, the majority of relapses transpired in patients with initial severe BP, with mucosal invasion, and those who restarted the original therapy, pointing to an elevated risk in this cohort. The 11 deceased patients constituted a high-risk subset distinguished by advanced age (median 74 years), a prevalence of melanoma, and severe BP. The duration from BP diagnosis to demise was briefer in this subset (median 3.7 months), with half of the patients succumbing within 4 months. Conclusion: ICI-BP is usually manageable through a stepwise therapeutic approach, and resuming ICI treatment after lesion remission is generally possible. Clinical decision-making must be tailored to the individual patient. Caution and careful monitoring are essential when reinitiating ICI in patients who initially presented with severe disease or mucosal involvement. For elderly patients, those with melanoma, and individuals experiencing severe BP, heightened vigilance is necessary concerning short-term prognostic risks. Systematic review registration: https://www.crd.york.ac.uk/prospero/ , identifier CRD420251172315
- 4 March 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1745011
Open AccessImmune checkpoint inhibitor-induced bullous pemphigoid: a systematic review of clinical characteristics and outcomes based on case reports
Objective: Immune checkpoint inhibitor-induced bullous pemphigoid (ICI-BP) is a rare and complex cutaneous immune-related adverse event (cirAE) that often impacts the continuation of ICI therapy. Currently, there are no prospective clinical studies addressing the optimal management of BP alongside ICI continuation, with existing evidence largely derived from case reports or series. This study systematically analyzes published case reports and series to compile evidence regarding the management of ICI-BP and ICI rechallenge, aiming to inform clinical practice. Methods: A comprehensive search of the PubMed, Embase, and Web of Science Core Collection (WoS CC) databases was conducted from their inception to identify eligible case reports and series. Relevant data were extracted using a standardized form. A total of 116 cases from 89 publications were included in the analysis. Results: There was no discernible disparity in the final response rate between patients with mild and severe BP (p > 0.05); however, the percentage of severe patients undergoing escalation therapy was notably higher (p < 0.001). This suggests that employing an active treatment approach based on disease severity effectively ameliorated the potentially graver prognosis in severe cases. Following BP management, 18 patients underwent rechallenge with ICI therapy, with an overall low BP recurrence rate (22.2%), indicating that most patients tolerated the resumption well. Nevertheless, the majority of relapses transpired in patients with initial severe BP, with mucosal invasion, and those who restarted the original therapy, pointing to an elevated risk in this cohort. The 11 deceased patients constituted a high-risk subset distinguished by advanced age (median 74 years), a prevalence of melanoma, and severe BP. The duration from BP diagnosis to demise was briefer in this subset (median 3.7 months), with half of the patients succumbing within 4 months. Conclusion: ICI-BP is usually manageable through a stepwise therapeutic approach, and resuming ICI treatment after lesion remission is generally possible. Clinical decision-making must be tailored to the individual patient. Caution and careful monitoring are essential when reinitiating ICI in patients who initially presented with severe disease or mucosal involvement. For elderly patients, those with melanoma, and individuals experiencing severe BP, heightened vigilance is necessary concerning short-term prognostic risks. Systematic review registration: https://www.crd.york.ac.uk/prospero/ , identifier CRD420251172315
- Open Access
- 2 February 2026
- Published by Taylor & Francis in Cell Adhesion & Migration
- Vol. 20 (1) , 2624204
Research on tissue-resident macrophages in the field of cancer research: a bibliometric analysis from 2004 to 2025
In the tumor microenvironment, tissue-resident macrophages (TRMs) promote malignant tumor progression, yet their tissue-specific heterogeneity and complex functions bring research challenges. This study analyzes the research status and trends of TRMs in oncology. Via VOSviewer, CiteSpace, R software and WoSCC, a visual bibliometric network was built for quantitative analysis, with future research directions explored in depth. The US leads in publications and academic influence, and the University of Washington tops in paper output. Research focuses on TRMs' origin, classification and tumor microenvironment functions; microglia and Kupffer cells are the most studied subsets. Current research centers on pathway exploration, immunotherapy and single-cell sequencing. This study summarizes TRMs' research status, hotspots and trends in oncology, providing valuable insights for relevant collaborators and institutions.
- 2 February 2026
- Published by Taylor & Francis in Cell Adhesion & Migration
- Vol. 20 (1) , 2624204
Open AccessResearch on tissue-resident macrophages in the field of cancer research: a bibliometric analysis from 2004 to 2025
In the tumor microenvironment, tissue-resident macrophages (TRMs) promote malignant tumor progression, yet their tissue-specific heterogeneity and complex functions bring research challenges. This study analyzes the research status and trends of TRMs in oncology. Via VOSviewer, CiteSpace, R software and WoSCC, a visual bibliometric network was built for quantitative analysis, with future research directions explored in depth. The US leads in publications and academic influence, and the University of Washington tops in paper output. Research focuses on TRMs' origin, classification and tumor microenvironment functions; microglia and Kupffer cells are the most studied subsets. Current research centers on pathway exploration, immunotherapy and single-cell sequencing. This study summarizes TRMs' research status, hotspots and trends in oncology, providing valuable insights for relevant collaborators and institutions.
- Open Access
- 10 December 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1661694
Traditional Chinese medicine as potential adjuvants for tumor vaccines: a review of types, mechanisms, and forms
Therapeutic cancer vaccines are increasingly recognized as a highly promising approach for tumor treatment; however, their clinical efficacy critically depends on the rational design of vaccine adjuvants. Natural compounds derived from Traditional Chinese Medicine (TCM) have emerged as attractive candidates for next-generation tumor vaccine adjuvants. In this review, we systematically summarize the chemical constituents of TCM-derived adjuvants reported in current research and categorize their mechanisms of action into four functional modalities: (i) immunostimulatory adjuvants that activate innate immune pathways; (ii) delivery-enhancing systems that improve antigen stability and facilitate targeting to antigen-presenting cells; (iii) integrated platforms that combine both immunostimulatory and delivery-enhancing functions; and (iv) other mechanisms involving non-canonical immunomodulatory activities. We further discuss current challenges in standardization, regulatory approval, and clinical translation, offering a roadmap for harnessing the potential of TCM in the rational design of cancer vaccines.
- 10 December 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1661694
Open AccessTraditional Chinese medicine as potential adjuvants for tumor vaccines: a review of types, mechanisms, and forms
Therapeutic cancer vaccines are increasingly recognized as a highly promising approach for tumor treatment; however, their clinical efficacy critically depends on the rational design of vaccine adjuvants. Natural compounds derived from Traditional Chinese Medicine (TCM) have emerged as attractive candidates for next-generation tumor vaccine adjuvants. In this review, we systematically summarize the chemical constituents of TCM-derived adjuvants reported in current research and categorize their mechanisms of action into four functional modalities: (i) immunostimulatory adjuvants that activate innate immune pathways; (ii) delivery-enhancing systems that improve antigen stability and facilitate targeting to antigen-presenting cells; (iii) integrated platforms that combine both immunostimulatory and delivery-enhancing functions; and (iv) other mechanisms involving non-canonical immunomodulatory activities. We further discuss current challenges in standardization, regulatory approval, and clinical translation, offering a roadmap for harnessing the potential of TCM in the rational design of cancer vaccines.
- Open Access
- 15 October 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1680551
Isolation of exosome-like nanovesicles from Yiqi Huoxue Jiedu decoction and their anti-ovarian cancer activity
Background: Ovarian cancer, the deadliest gynecologic malignancy, is marked by high recurrence and poor prognosis. Exosome-like nanovesicles (ELNVs) derived from decocted traditional Chinese medicine (TCM) formulas encapsulate key bioactive components, and show promising therapeutic efficacy with good biocompatibility and targeting ability. However, research on ELNV extraction methodologies remains limited. Yiqi Huoxue Jiedu Decoction (YQHXJDD), an empirically validated TCM formula for ovarian cancer, lacks systematic investigation into its ELNV isolation protocols and therapeutic mechanisms. This study took YQHXJDD as the research subject, with a focus on extracting ELNVs from this TCM formula and validating their anti-ovarian cancer activity.Methods: YQHXJDD was extracted using varied decoction protocols. ELNVs were enriched by gradient and ultracentrifugation, resuspended in phosphate-buffered saline, and were characterized by size and concentration using transmission electron microscopy (TEM) and nanoparticle tracking analysis (NTA). The number of ELNVs enriched per dose of YQHXJDD was calculated to screen the decoction method that maximized ELNV yield and aligned with clinical medication practices. The colloidal stability of YQHXJDD ELNVs was evaluated via zeta potential measurement, and the bioactive components of YQHXJDD ELNVs were identified using untargeted metabolomics and RNA sequencing. An ID8-Luc peritoneal tumor-bearing mouse model was established and randomized into three groups: model, YQHXJDD, and YQHXJDD ELNVs. Mice received oral gavage for 3 consecutive weeks. Tumor burden was monitored via in vivo small animal imaging. Immunofluorescence was used to quantify CD86, CD206, CD4, and CD8 fluorescence in omental tumors. Luminex xMAP® Multiplex Assay was used to detect 36 cytokines/chemokines in serum, and flow cytometry was used to analyze splenic immune cell proportions and activity.Results: The creation efficiency of ELNVs formed during decoction is the highest with the optimal protocol, which is identified for maximizing YQHXJDD ELNV yield and involves 40 min of high-heat treatment followed by an additional 30 min of low-heat treatment. Zetaview-based zeta potential analysis demonstrated that YQHXJDD ELNVs by this protocol had an average zeta potential of −35.52 mV, indicating favorable colloidal stability. Untargeted metabolomics analysis revealed “Lipids and lipid-like molecules” as the most abundant metabolite superclass (34.98% of total metabolites), while “Carboxylic acids and derivatives” represented the dominant subclass (11.66%). Regarding small RNAs, those enriched in YQHXJDD ELNVs were confirmed to be typical, functionally active small RNAs. Notably, miR8783 and other miRNAs exhibited significantly high expression, along with high conservation and abundance across samples, suggesting they might act as core regulators of YQHXJDD ELNV biological functions. In in vivo assessments, compared with the model group, YQHXJDD ELNVs significantly inhibited ovarian cancer growth and metastasis, increased tumor necrosis factor-α (TNF-α) levels in mouse peripheral blood, and positively regulated the M1/M2 macrophage ratio and CD4+/CD8+ T cell ratio in omental tissues (all P < 0.05). However, YQHXJDD ELNVs had no significant effect on the proportions of splenic effector T cells, natural killer (NK) cells, activated CD8+ T cells, and activated NK cells (all P ≥ 0.05).Conclusion: The decoction ELNVs isolated from YQHXJDD can inhibit the growth and dissemination of ovarian cancer. The miRNAs and lipid components encapsulated in these ELNVs are presumed to be the critical mediators of these anti-ovarian cancer effects.
- 15 October 2025
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 16, 1680551
Open AccessIsolation of exosome-like nanovesicles from Yiqi Huoxue Jiedu decoction and their anti-ovarian cancer activity
Background: Ovarian cancer, the deadliest gynecologic malignancy, is marked by high recurrence and poor prognosis. Exosome-like nanovesicles (ELNVs) derived from decocted traditional Chinese medicine (TCM) formulas encapsulate key bioactive components, and show promising therapeutic efficacy with good biocompatibility and targeting ability. However, research on ELNV extraction methodologies remains limited. Yiqi Huoxue Jiedu Decoction (YQHXJDD), an empirically validated TCM formula for ovarian cancer, lacks systematic investigation into its ELNV isolation protocols and therapeutic mechanisms. This study took YQHXJDD as the research subject, with a focus on extracting ELNVs from this TCM formula and validating their anti-ovarian cancer activity.Methods: YQHXJDD was extracted using varied decoction protocols. ELNVs were enriched by gradient and ultracentrifugation, resuspended in phosphate-buffered saline, and were characterized by size and concentration using transmission electron microscopy (TEM) and nanoparticle tracking analysis (NTA). The number of ELNVs enriched per dose of YQHXJDD was calculated to screen the decoction method that maximized ELNV yield and aligned with clinical medication practices. The colloidal stability of YQHXJDD ELNVs was evaluated via zeta potential measurement, and the bioactive components of YQHXJDD ELNVs were identified using untargeted metabolomics and RNA sequencing. An ID8-Luc peritoneal tumor-bearing mouse model was established and randomized into three groups: model, YQHXJDD, and YQHXJDD ELNVs. Mice received oral gavage for 3 consecutive weeks. Tumor burden was monitored via in vivo small animal imaging. Immunofluorescence was used to quantify CD86, CD206, CD4, and CD8 fluorescence in omental tumors. Luminex xMAP® Multiplex Assay was used to detect 36 cytokines/chemokines in serum, and flow cytometry was used to analyze splenic immune cell proportions and activity.Results: The creation efficiency of ELNVs formed during decoction is the highest with the optimal protocol, which is identified for maximizing YQHXJDD ELNV yield and involves 40 min of high-heat treatment followed by an additional 30 min of low-heat treatment. Zetaview-based zeta potential analysis demonstrated that YQHXJDD ELNVs by this protocol had an average zeta potential of −35.52 mV, indicating favorable colloidal stability. Untargeted metabolomics analysis revealed “Lipids and lipid-like molecules” as the most abundant metabolite superclass (34.98% of total metabolites), while “Carboxylic acids and derivatives” represented the dominant subclass (11.66%). Regarding small RNAs, those enriched in YQHXJDD ELNVs were confirmed to be typical, functionally active small RNAs. Notably, miR8783 and other miRNAs exhibited significantly high expression, along with high conservation and abundance across samples, suggesting they might act as core regulators of YQHXJDD ELNV biological functions. In in vivo assessments, compared with the model group, YQHXJDD ELNVs significantly inhibited ovarian cancer growth and metastasis, increased tumor necrosis factor-α (TNF-α) levels in mouse peripheral blood, and positively regulated the M1/M2 macrophage ratio and CD4+/CD8+ T cell ratio in omental tissues (all P < 0.05). However, YQHXJDD ELNVs had no significant effect on the proportions of splenic effector T cells, natural killer (NK) cells, activated CD8+ T cells, and activated NK cells (all P ≥ 0.05).Conclusion: The decoction ELNVs isolated from YQHXJDD can inhibit the growth and dissemination of ovarian cancer. The miRNAs and lipid components encapsulated in these ELNVs are presumed to be the critical mediators of these anti-ovarian cancer effects.